CRISPR Therapeutics' (CRSP) Market Outperform Rating Reiterated at Citizens Jmp

Key Points

• Citizens JMP reiterated its “market outperform” rating on CRISPR Therapeutics and set an $80 price target, implying 38.6% upside from the previous close.
• Analyst sentiment remains positive overall, with CRISPR Therapeutics holding a consensus “Moderate Buy” rating and an average price target of $68.06. Targets from other firms range from $55 to $82.
• CRISPR Therapeutics reported a quarterly loss of $0.94 per share on $10.18 million in revenue, while institutional investors own approximately 69.2% of the company’s stock.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report)'s stock had its "market outperform" rating reiterated by equities researchers at Citizens Jmp in a report issued on Monday,Benzinga reports. They currently have a $80.00 price target on the stock. Citizens Jmp's price target would indicate a potential upside of 38.60% from the company's previous close.

Other research analysts have also issued research reports about the company. Needham & Company LLC reissued a "buy" rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research note on Monday. UBS Group set a $80.00 price objective on CRISPR Therapeutics in a research report on Friday, June 12th. Morgan Stanley set a $60.00 target price on CRISPR Therapeutics and gave the company an "equal weight" rating in a research note on Thursday, June 11th. The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Finally, Citigroup reissued a "market outperform" rating on shares of CRISPR Therapeutics in a research note on Tuesday, August 25th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $68.06.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $57.72 on Monday. CRISPR Therapeutics has a 12-month low of $44.12 and a 12-month high of $78.48. The firm has a market cap of $5.58 billion, a price-to-earnings ratio of -12.13 and a beta of 1.74. The company's 50-day moving average is $53.62 and its two-hundred day moving average is $52.73. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. The firm had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. Research analysts expect that CRISPR Therapeutics will post -4.47 EPS for the current year.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Cerity Partners LLC raised its holdings in CRISPR Therapeutics by 3.0% in the second quarter. Cerity Partners LLC now owns 6,541 shares of the company's stock valued at $318,000 after acquiring an additional 190 shares in the last quarter. Peapack Gladstone Financial Corp lifted its position in shares of CRISPR Therapeutics by 3.0% during the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company's stock worth $339,000 after purchasing an additional 200 shares during the last quarter. Allworth Financial LP lifted its position in shares of CRISPR Therapeutics by 2.7% during the fourth quarter. Allworth Financial LP now owns 9,550 shares of the company's stock worth $501,000 after purchasing an additional 249 shares during the last quarter. Meeder Advisory Services Inc. grew its stake in CRISPR Therapeutics by 6.6% in the fourth quarter. Meeder Advisory Services Inc. now owns 4,392 shares of the company's stock worth $230,000 after purchasing an additional 270 shares in the last quarter. Finally, IFP Advisors Inc increased its holdings in CRISPR Therapeutics by 29.9% in the fourth quarter. IFP Advisors Inc now owns 1,250 shares of the company's stock valued at $66,000 after buying an additional 288 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source